Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report

Figure 1 Responses of lung and brain lesions to afatinib. A: Baseline before treatment; B: After 3 mo of afatinib treatment: Lung lesion responded partially and brain lesion was stable; C: After 10 mo of afatinib treatment: Lung lesion remained stable and brain lesion progressed. Only the target brain metastatic lesion was displayed and indicated by the orange arrow.